Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Blood Cancer J
.
2022 Jul 11;12(7):108.
doi: 10.1038/s41408-022-00705-6.
Authors
Benjamin A Derman
1
,
Andrzej J Jakubowiak
2
,
Michael A Thompson
3
4
Affiliations
1
Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA. bderman@medicine.bsd.uchicago.edu.
2
Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
3
Tempus Labs, Chicago, IL, USA.
4
Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, USA.
PMID:
35821020
PMCID:
PMC9276661
DOI:
10.1038/s41408-022-00705-6
No abstract available
Publication types
Letter
MeSH terms
Humans
Multiple Myeloma* / drug therapy
Neoplasm, Residual
Surveys and Questionnaires